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of neutrophil extracellular traps, chromatin fibers 
released from dying neutrophils, leading to a pro‑
thrombotic state, oxidative stress, and atheroscle‑
rosis progression.5 The association between can‑
cer and ACS is complex. ACS may occur before or 
after establishing the diagnosis of cancer. Some‑
times the diagnosis is made during hospitaliza‑
tion for ACS.
ACS may be induced by cancer treatment (ie, 
chemotherapy, radiotherapy, or surgical treat‑
ment). Highly prothrombotic effects have been 
observed in patients treated with cisplatin (ACS 
in up to 2% of patients), erythropoietin, gem‑
citabine, 5 ‑fluorouracil (ACS in up to 10%), gran‑
ulocyte colony‑stimulating factors, and bevaci‑
zumab (ACS in up to 4%). Use of pyrimidine an‑
alogues requires close monitoring for ACS. Over‑
all, previous chemotherapy should be considered 
a risk factor of coronary artery disease. In most 
cases,  ACS in cancer patients develops in the ar‑
teries affected by atherosclerosis as a manifesta‑
tion of coronary artery disease in the presence of 
cardiovascular risk factors, predominantly in el‑
derly patients, and it occurs independently of an‑
ticancer treatment. It may be also associated with 
complications from cancer or not be associated 
Epidemiology and mechanisms of acute coronary syn-
drome in cancer A modern approach to the diag‑
nosis of acute coronary syndrome (ACS) is not 
limited to confirming the presence of critical cor‑
onary artery stenosis and myocardial ischemia 
due to atherosclerotic plaque rupture or erosion 
(type 1 myocardial infarction [MI]). The clinical 
spectrum of ACS encompasses also type 2 MI sec‑
ondary to ischemia caused by an imbalance be‑
tween oxygen demand and supply, type 3 MI re‑
sulting in sudden cardiac death, type 4a associated 
with percutaneous coronary interventions (PCIs), 
type 4b associated with stent thrombosis, and fi‑
nally, type 5 associated with cardiovascular sur‑
gery.1,2 The key to understanding the pathophys‑
iology of ACS is ischemia, which is also caused by 
endothelial and microcirculatory dysfunction, va‑
sospasm, as well as enhanced inflammatory state 
and inherited or acquired prothrombotic tenden‑
cy.3 The pathogenesis of ACS often involves the si‑
multaneous presence of several different causes of 
ischemia. All these considerations on the patho‑
physiology of ACS are particularly important in 
patients with concomitant cancer at various stag‑
es of its diagnosis and treatment.4 A new common 
mechanism linking cancer with ACS is formation 
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ABsTRACT
Cancer at various stages and therapy is observed in about 15% of patients with acute coronary syn-
drome (ACS). Current guidelines for invasive and conservative treatment of ACS cannot be applied to 
all patients with cancer. The choice of antiplatelet and anticoagulant drugs should be individualized with 
clopidogrel as a key P2Y12 inhibitor in this population. Major challenges of therapy in patients with ACS 
and cancer include limitations for the use of the recommended antithrombotic therapy (particularly in 
case of cancer-related thrombocytopenia or when anticoagulation is needed due to concomitant atrial 
fibrillation or venous thromboembolism), the management of bleeding complications, eligibility criteria for 
cancer surgery, and reinitiation of chemotherapy or radiotherapy after ACS. This review summarizes the 
current evidence and our own experience in the treatment of ACS in cancer patients. Since prognosis has 
considerably improved in many cancer patients in the last decade, optimal therapy of ACS may increase 
the life expectancy and reduce the risk of adverse coronary events after ACS in this high-risk population. 
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Clinical presentation of acute coronary syndrome in 
cancer The clinical presentation of ACS in can‑
cer patients is often different from that observed 
in the general population.14-16 The prevalence of 
silent ischemia is higher in cancer patients, pos‑
sibly due to neurotoxic effects of chemothera‑
py and altered perception of angina. Dyspnea is 
observed more often than angina in cancer pa‑
tients. There are various misleading abnormali‑
ties on electrocardiograms that may be caused 
by tumor infiltration of the myocardium, cere‑
bral bleeds, chemotherapy, pulmonary embo‑
lism, and others. Elevated cardiac troponin levels 
do not necessarily indicate ACS. In 85% of cases, 
ACS manifests as non–ST ‑segment elevation MI 
(NSTEMI), and in 15%, as ST ‑segment elevation 
MI (STEMI). Moreover, 1 in 10 patients presents 
with Takotsubo cardiomyopathy.
According to current management guidelines, 
every patient with ACS and cancer should be con‑
sidered for interventional treatment, with op‑
timal medical therapy prior to admission and 
during hospitalization. Importantly, the pres‑
ence of cancer in patients with ACS undergoing 
PCI increases the risk of cardiovascular events 
and bleeding complications, especially gastro‑
intestinal hemorrhage and hematuria as well 
as adversely affects in ‑hospital and long ‑term 
prognosis.16-20 In the BleeMACS project, a mul‑
ticenter observational registry that enrolled pa‑
tients with ACS, it has been reported that 6.4% 
suffered from concomitant cancer, and they were 
older, and more frequently had NSTEMI and se‑
vere comorbidities compared with the remain‑
der.17 Importantly, death or re infarction as well 
as bleedings after 1‑year follow ‑up were more 
common in the cancer group (15.2% vs 5.3% and 
6.5% vs 3.0%, respectively), leading to the con‑
clusion that cancer is the strongest predictor of 
the 2 endpoints.17 A study on a large Canadian 
cohort of 22 907 cancer patients with acute MI 
recruited between 1995 and 2013 and followed 
for 10 years reported that at 30 years, cancer, but 
not recurrent ACS or stroke, is associated with 
higher morality (adjusted hazard ratio, 1.12; 95% 
confidence interval, 1.01–1.17) and to a similar 
extent after 1 year and during long ‑term follow‑
‑up.18 There was no difference in the rate of death 
with regard to the time from cancer diagnosis to 
MI, which underscores the value of cardiac as‑
sessment in cancer survivors.18 Higher mortal‑
ity in patients with MI with a history of cancer 
is multifactorial. This finding probably results 
not only from cancer itself but is also associated 
with the clinical characteristics of these patients, 
who are more often older, suffer from arterial 
hypertension, diabetes, chronic kidney disease, 
and have a history of ACS and CABG as well as 
bleeding complications. Moreover, the outcomes 
of PCI and conservative treatment may differ de‑
pending on the stage of cancer, diagnostic evalu‑
ation, and treatment.7 Stage 1 (ie, from diagno‑
sis to treatment completion) is associated with 
higher thrombotic risk. Stage 2 (ie, prolonged 
with cancer at all. Cancer at various stages and 
therapy is observed in about 15% of patients with 
ACS.6 Clinical data show that cardiovascular death 
is one of the main causes of in ‑hospital mortal‑
ity in cancer and noncancer patients with ACS 
undergoing PCI.7
Unfortunately, so far prospective studies as‑
sessing the efficacy and safety of ACS treatment 
have excluded patients with active cancer. As a re‑
sult, current guidelines for invasive and conserva‑
tive treatment of ACS cannot be easily applied to 
all patients with cancer. There is growing aware‑
ness that cancer treatment has negative effects 
on the optimal management of ACS, and vice 
versa.8 Therefore, from a clinical perspective, it 
is extremely important to assess the cardiovas‑
cular and noncardiovascular risk in patients with 
ACS and concomitant cancer.9 Such an approach 
allows to avoid complications of aggressive anti‑
platelet and anticoagulant therapy or revascular‑
ization with PCI or coronary artery bypass graft‑
ing (CABG).
The incidence of ACS in patients with newly 
diagnosed cancer increases in the first 6 months 
since diagnosis and then decreases after a year to 
increase again in more advanced stages.10,11 ACS 
occurs in patients with various cancers, most of‑
ten in those with lung, gastric, or pancreatic can‑
cer. The occurrence of ACS in patients with can‑
cer is associated with classic risk factors such as 
hypertension, diabetes, obesity, or smoking, but 
also with several prothrombotic factors secreted 
by the tumor itself or expressed on its surface; 
chemotherapy and radiotherapy can also exert 
prothrombotic, proinflammatory, and vasospas‑
tic actions.4,11
The occurrence of ACS in the cancer patient 
raises numerous concerns about the manage‑
ment, which should not only be effective but also 
safe.12,13 The common questions are as follows: 
Are complaints reported by the patient typical 
for ACS? Which antiplatelet and anticoagulant 
drugs and what regimens should be used? How 
to balance the risk of thrombosis against the risk 
of bleeding? How to manage patients with bleed‑
ing complications? How to modify treatment of 
ACS in patients with thrombocytopenia? How to 
perform invasive revascularization (PCI, CABG)? 
What should be the indications and eligibility cri‑
teria for cancer surgery following ACS? When to 
restart chemotherapy or radiotherapy after ACS?
Key messages
•	  Cancer at various stages of development and 
therapy is observed in about 15% of patients with 
ACS.
•	  The incidence of ACS in patients with newly 
diagnosed cancer increases in the first 6 months 
since diagnosis and decreases at 1 year.
•	  ACS most often occurs in patients with lung, 
gastric, and pancreatic cancer.
•	  Each patient with cancer should be screened 
for classic cardiovascular risk factors.
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•	  Patients with metastatic cancer who develop 
STEMI or NSTEMI benefit from PCI.
Medical therapy in patients with acute coronary syn-
drome and cancer To maintain the beneficial ef‑
fects of revascularization in patients with ACS, 
optimal medical therapy is required, which has 
been shown to be effective in reducing serious 
cardiovascular events during long ‑term follow‑
‑up.28 Each patient with ACS, both with and with‑
out cancer, should be considered for the rec‑
ommended antiplatelet treatment along with 
a statin, angiotensin ‑converting enzyme inhibitor 
(ACEI) (or angiotensin receptor blockers [ARBs] 
in case of ACEI intolerance), mineralocorticoid 
receptor antagonist, and β ‑blocker.29 Optimal 
medical therapy was shown to reduce the rate 
of serious cardiovascular events by 32% during 
a 12 ‑month follow ‑up in patients with ACS and 
cancer undergoing PCI.30 However, both invasive 
treatment and optimal medical therapy have been 
shown to be underused in cancer patients with 
ACS.17-19 Nevertheless, in the BleeMACS study, 
β ‑blockers, ACEIs/ARBs, statins, and antiplate‑
let agents were shown to reduce the risk of death 
and re infarction at 1 year since ACS.17 In Cana‑
da, ACEIs (or ARBs) and statins have been found 
to be slightly less often prescribed in cancer pa‑
tients after ACS, while the use of clopidogrel, ni‑
trates, spironolactone, calcium channel blockers, 
and β ‑blockers was similar in cancer and noncan‑
cer patients.18
In the case of long ‑term secondary prevention 
after ACS in patients with cancer, potential drug 
interactions with chemotherapeutics should be 
considered.31-33 In particular, paclitaxel affects 
CPY2C8 ‑mediated metabolism of simvastatin, 
atorvastatin, lovastatin, and fluvastatin.34 Clop‑
idogrel, a prodrug metabolized in the liver to its 
active form, may have lower antiplatelet activi‑
ty in patients with liver injury due to cancer or 
the use of chemotherapeutics.8 The androgen‑
‑receptor blocker spironolactone reduces the effec‑
tiveness of chemotherapy in patients with breast 
cancer, and therefore it should be replaced by 
the selective mineralocorticoid receptor antago‑
nist eplerenone.35,36
Due to several drug–drug interactions and com‑
mon unstable anticoagulation in part driven by in‑
teractions with diet, warfarin could be less effec‑
tive than low ‑molecular ‑weight heparin (LMWH) 
in stable cancer patients with ACS; therefore, 
LMWH is the preferred option in such patients 
when, apart from DAPT, anticoagulation is rec‑
ommended (particularly in venous thromboem‑
bolism [VTE]).8,37,38 Finally, the use of class 3 an‑
tiarrhythmic drugs (ie, amiodarone and sotalol) 
in combination with angiogenesis inhibitors may 
prolong the QT interval leading to life ‑threatening 
ventricular arrhythmia.39
Key messages
•	  Each cancer patient with ACS should be consid‑
ered for optimal medical therapy with antiplate‑
let drug or drugs, statins, ACEIs (or ARBs in case 
survival after treatment completion) is associ‑
ated with increased thromboembolic risk due to 
thrombocytosis, leukocytosis, and infection. Fi‑
nally, stage 3 (ie, long ‑term survival) may be as‑
sociated with cardiotoxic effects of chemother‑
apy, in particular anthracyclines and kinase in‑
hibitors, and radiotherapy.
To optimize interventional treatment and 
minimize bleeding events, it is important to 
use the transradial and not the transfemoral 
approach.21 The transradial access is much safer 
in case of bleeding and is more convenient for 
the patient. On the other hand, the transfemo‑
ral access poses a higher risk of retroperitone‑
al bleeding, a major event, which may be fatal, 
especially if dual antiplatelet therapy (DAPT) 
is used in a patient with thrombocytopenia. 
The transfemoral approach should not be used 
in such patients except those in whom the tran‑
sradial access had been used several times be‑
fore, in women after total mastectomy, in those 
with abnormal Allen test results, and in individ‑
uals on hemodialysis.22
Importantly, long ‑term cardiovascular progno‑
sis in patients with ACS undergoing PCI does not 
differ between individuals with newly diagnosed 
cancer and those with a history of cancer (most 
often lung, breast, and prostate cancer).23 More‑
over, patients with metastatic cancer who devel‑
op STEMI or NSTEMI benefit from PCI in terms 
of a 2‑ to 3 ‑fold reduction in in ‑hospital mortal‑
ity.24 However, based on the available data, PCI 
is performed only in every fourth cancer patient 
with STEMI and in every tenth cancer patient 
with NSTEMI. Of note, it has been demonstrat‑
ed that invasive therapy of ACS results in 5 ‑year 
survival of 99% of patients with metastatic pros‑
tate cancer, and as few as 7% of those with met‑
astatic pancreatic cancer.25 Therefore, each ACS 
patient with cancer, regardless of the presence of 
distant metastases or not, should be considered 
for invasive strategy. The potential clinical ben‑
efits of PCI in these patients are not affected by 
radiotherapy.26 However, previous radiotherapy 
for breast cancer in patients with ACS has been 
shown to increase the risk of recurrent ACS in 
a 12 ‑year follow ‑up.27
Key messages
•	  The clinical presentation of ACS in cancer pa‑
tients is often different from that observed in 
the general population.
•	  ACS manifests predominantly as NSTEMI.
•	  The stage of cancer since diagnosis to treat‑
ment completion is associated with higher ve‑
nous thromboembolic risk.
•	  Anticancer treatment may increase thrombot‑
ic risk and lead to cardiotoxic effects of chemo‑
therapy and radiotherapy.
•	  The presence of cancer in patients with ACS un‑
dergoing PCI increases cardiovascular and bleed‑
ing risk (especially gastrointestinal and urinary 
bleeding), as well as adversely affects in ‑hospital 
and long ‑term prognosis.
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used for at least 1 month, while the decision to 
continue treatment for 3 to 6 months should de‑
pend on additional factors increasing the risk of 
recurrent ischemia related to the extent of coro‑
nary lesions and procedure performed, as well as 
the presence of clinically relevant bleeding com‑
plications. After this period, clopidogrel should 
be stopped and ASA alone should be continued. 
In the case of ASA intolerance or bleeding, ASA 
should be switched to clopidogrel. In patients 
with cancer who experience ACS, PCI with bare 
metal stent implantation should be performed, 
and DAPT should be administered if the platelet 
count exceeds 30 000/µl. It is recommended that 
chemotherapy or surgery should be delayed by 
4 weeks. After drug ‑eluting stent (DES) implanta‑
tion, DAPT should be administered for 12 months 
provided no bleeding occurs42; however, the im‑
plantation of third ‑generation DESs implicates 
shortening of the duration of DAPT that can be 
safely reduced to 3 to 6 months. Such a thera‑
py should be considered if the platelet count ex‑
ceeds 30 000/µl and the patient does not require 
an urgent surgery or aggressive chemotherapy.43 
Baloon angioplasty is recommended if the plate‑
let count ranges from 10 000 to 30 000/µl, or if 
DAPT cannot be used, or if chemotherapy or sur‑
gery is scheduled within the next 4 weeks.22 With 
balloon angioplasty, DAPT should be administered 
for at least 2 weeks (provided that the platelet 
count exceeds 30 000/µl).
The need for urgent surgery following ACS 
in cancer patients is a challenge. Irrespective 
of the stent implanted, clopidogrel should be 
stopped and ASA should be continued in the peri‑
operative period. After the surgery, typically af‑
ter 24 to 48 hours, clopidogrel at a loading dose 
of 300 mg can be restarted and then tapered to 
75 mg/d provided the hemostasis is maintained.
The duration of DAPT after stent implantation 
in patients on chemotherapy and radiotherapy is 
still under debate, as the data on the effect of this 
treatment on reendothelization of stents are lack‑
ing.12 It is recommended to assess the possibility 
of optimal stent extension in these patients, using 
intravascular ultrasound or optical coherence to‑
mography.22 In general, the decision on the choice 
of antiplatelet drugs should be tailored to indi‑
vidual patients depending on the stage of cancer 
and the need for surgery after ACS and/or PCI.
Anticoagulant therapy combined with antiplatelet 
agents in patients with acute coronary syndrome and 
cancer The management of patients with ACS 
and cancer who have indications for chronic anti‑
coagulation (eg, mechanical heart valve, nonval‑
vular atrial fibrillation [NVAF], VTE, or high ‑risk 
thrombophilia [eg, antiphospholipid syndrome, 
antithrombin deficiency]) is particularly challeng‑
ing due to high risk of bleeding and thrombosis.
Cancer occurs in about 2.5% of patients with 
NVAF, the most common indication for antico‑
agulation, and this arrhythmia is associated with 
a 5 ‑fold increase in stroke risk, poor prognosis, 
of ACEI intolerance), mineralocorticoid receptor 
antagonists, and β ‑blockers.
•	  In the case of long ‑term secondary preven‑
tion after ACS in cancer patients, potential in‑
teractions with chemotherapeutics should be 
considered.
Antiplatelet therapy of patients with acute coronary 
syndrome and cancer Antiplatelet therapy, which 
is a standard management in the general popula‑
tion with ACS, constitutes a challenge in patients 
with cancer. These patients are at high risk of 
stent thrombosis and bleeding complications that 
are often aggravated by the presence of throm‑
bocytopenia.40 Currently, the first ‑choice anti‑
platelet drugs in ACS patients with cancer are 
acetylsalicylic acid (ASA; 300/75 mg) and clopi‑
dogrel (300–600/75 mg) (FIguRE 1A).41 Ticagrelor 
and prasugrel should not be used owing to high‑
er risk of bleeding in cancer patients. As conser‑
vative treatment, ASA with clopidogrel should be 
TABLE 1 Interactions between anticancer drugs and non–vitamin K antagonist oral 
anticoagulants
Contraindicated/not recommended
Increased/decreased anticoagulant effects
No relevant drug–drug interaction 
anticipated
Vinblastine ↓ Metotrexate
Doxorubicin ↓ Pemetrexed, purine analogsa, 
pyrimidine analogsb
Imatinib, crizotinib ↑ Topotecan
Vandetanib, sunitinib ↓ Irinotecan
Abiraterone ↑ Daunorubicin
Enzalutamide ↓ Mitoxantrone
Cyclosporine ↑ Busulfan
Dexamethasone ↓ Bendamustine
Tacrolimus ↑ Chlorambucil
Melphalan
Carmustine
Procarazine
Dacarbazine
Temozolomide
Carboplatin
Bleomycin
Dactinomycin
Mitomycin C
Erlotinib, gefitinib
Monoclonal antibodies
(eg, rituximab, bevacizumab)
Flutamide
Letrozole
Fulvestrant
Raloxifene
Leuprolide, Mitotane
a Purine analogs: mercaptopurine, thioguanine, pentostatin, cladribine, clofarabine, 
fludarabine
b Pyrimidine analogs: fluorouracil, capeticabine, cytarabine, gemcitabine, azacitadine, 
decitabine
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they are increasingly used in cancer patients with 
NVAF, which poses problems in acute myocardial 
ischemia.46 A recent Danish population ‑based co‑
hort study has demonstrated that 1‑year risks of 
bleeding and thromboembolic events were similar 
in patients with NVAF with and without cancer re‑
ceiving NOAC and vitamin K antagonist (VKA).46 
Of note, as few as 27% of cancer patients were 
diagnosed within 2 years preceding the ACS.46 In 
American NOAC users with AF and cancer, lower 
or similar rates of bleeding and stroke were ob‑
served compared with warfarin users.47
Cancer patients on anticoagulant therapy 
with VKA or a NOAC, who experience an ACS, 
should be considered to be temporarily switched 
to LMWH, particular patients on chemothera‑
py (FIguRE 1B). The rationale for such an approach 
is an  easier control of anticoagulation with 
LMWH, which mostly does not require laboratory 
and mortality rates of 20% to 25% at 30 days.44 
It has been reported that cancer and its therapy 
contribute to increased prevalence of NVAF, in 
part due to comorbidities, anticancer treatment, 
and cancer ‑associated factors, including dehydra‑
tion, inflammation, and others, and the risk of 
thromboembolic complications.
In cancer patients, non–vitamin K antagonist 
oral anticoagulants (NOACs), including dabiga‑
tran, rivaroxaban, apixaban, and edoxaban (un‑
available in Poland until April 2018), should be 
used with caution.45 Active cancer was an exclu‑
sion criterion in most studies performed in pa‑
tients with AF and VTE to evaluate the efficacy 
and safety of all NOACs. Several drug–drug in‑
teractions can hamper the use of NOACs in can‑
cer; however, strong interactions are infrequent, 
as shown in TABLE 1.44 Despite limited evidence on 
the efficacy and safety of NOACs in this disease, 
FIguRE 1 Antithrombotic treatment of cancer patients with acute coronary syndromes (ACSs) based on current 
guidelines and own experience;  A – patients without indication for anticoagulation; B – patients with previous venous 
thromboembolism or other indications for anticoagulation, who may be treated with dual antiplatelet therapy up to 12 
months depending on bleeding risk; C – patients with atrial fibrillation treated with oral anticoagulants with low to 
moderate bleeding risk (mainly patients after more than 1 year since cancer diagnosis). Low -molecular -weight -heparin 
could be considered as an alternative to oral anticoagulants if bleeding risk is high. 
Acetylsalicylic acid (ASA): 75–100 mg/d once daily; vitamin K antagonist (VKA; warfarin, acenocoumarol) with a target 
international normalized ratio between 2 to 2.5, with its measurements every 1 to 2 weeks; low -molecular -weight 
heparin (LMWH; enoxaparin, preferentially subcutaneously) at an intermediate dose; optimization using anti -Xa activity 
could be used; non–vitamin K antagonist oral anticoagulant (NOAC): dabigatran, 2 × 110 mg/d; rivaroxaban, 15 mg/d; 
apixaban, 2 × 5 mg/d or 2 × 2.5 mg/d (reduction if 2 of the 3 criteria are met: weight ≤60 years, age ≥80 years, or 
creatinine ≥133 uM). Prolonged use of antiplatelet agents at high risk of myocardial ischemia following ACS including 
stenting of the left main coronary artery, or proximal descending artery, proximal bifurcation, stent thrombosis etc, and 
low bleeding risk.
ASA + clopidogrel 
ASA + clopidogrel Clopidogrel 
(if bleeding consider clopidogrel alone) ASA
Months
10
ACS
6 12
ASA + clopidogrel
+ LMWH 
ASA + clopidogrel
+VKA/MWH   
Clopidogrel + VKA/MWH VKA/NOAC alone
Months
1 6 120
ACS
ASA + clopidogrel
+ VKA/NOAC
ASA + clopidogrel 
+ VKA/NOAC Clopidogrel + VKA/NOAC VKA/NOAC alone
Months
1 6 120
ACS
A
C
B
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In case of an urgent surgery for cancer in pa‑
tients with ACS, clopidogrel should be stopped 
5 days before the planned surgery, while ASA 
should be continued. After surgery, clopidogrel 
should be restarted, first at a loading dose of 
300 mg, followed by a maintenance dose of 75 mg 
24 to 72 hours after surgery provided that hemo‑
stasis is maintained.12 In patients at high throm‑
botic risk, bridging therapy with intravenous (IV) 
glycoprotein (GP) IIb/IIIa ‑receptor inhibitors (ti‑
rofiban or eptifibatide) may be considered after 
discontinuation of clopidogrel. The bridging ther‑
apy should be started 3 days before the surgery 
and discontinued 4 to 6 hours before the proce‑
dure.48 Such an approach is used within the first 
weeks since ACS, in particular within the first 
28 days.
If an urgent life ‑saving surgery is required in 
patients on DAPT, the risk of excessive periop‑
erative bleeding should be accepted, and plate‑
let concentrate should be used if necessary. Pro‑
phylactic infusion of platelet concentrates in pa‑
tients on DAPT is not recommended in this set‑
ting; only an extremely low platelet count requires 
such therapy prior to surgery.
Replacement of antiplatelet drugs with stan‑
dard heparin or LMWH to reduce bleeding risk 
is not recommended because it has been report‑
ed that such a strategy is associated with a 10‑ 
to 12 ‑fold higher risk of serious cardiovascular 
events and a 2 ‑fold higher risk of bleeding.
Another issue is surgery in cancer patients with 
a history of ACS.49 Preferably, such operations 
should be performed in the hospital where PCI 
could be performed on the 24/7 basis if needed. 
Of note, breast cancer surgery, thyroid gland op‑
eration, reconstructive, gynecological, and mi‑
nor urological interventions are considered low‑
‑risk procedures.12 On the other hand, stomach 
and major urological surgeries, as well as most 
transplantations, are moderate ‑risk procedures.
Key messages
•	  Patients with ACS and cancer are at high risk 
of stent thrombosis and bleeding that are often 
aggravated by the presence of thrombocytopenia.
•	  The choice of antiplatelet and anticoagulant 
drugs should be individualized depending on 
the stage of cancer and the need for surgery af‑
ter ACS and/or PCI.
•	  Ticagrelor and prasugrel should not be used in 
cancer patients.
•	  In cancer patients who experience ACS, PCI 
with bare metal stents should be performed, and 
DAPT should be administered if the platelet count 
exceeds 30 000/µl.
•	  With third ‑generation DESs, the duration of 
DAPT can be safely shortened to 3 to 6 months 
and should be considered if the platelet count 
exceeds 30 000/µl and the patient has no indica‑
tions for an urgent surgery or chemotherapy.
•	  Patients on previous anticoagulant therapy, ei‑
ther with a VKA or a NOAC, should be switched 
to LMWH if ACS occurs.
monitoring as compared with VKAs. LMWH also 
facilitates the therapeutic decision of oncologists 
and surgeons, and it has been shown to be more 
effective than VKAs in cancer patients.37 Of im‑
portance, subtherapeutic doses of LMWH com‑
monly administered could be ineffective in stroke 
prevention among cancer patients with NVAF, 
given the lack of high quality data to support 
their use in this disease. Importantly, LMWH 
are even contraindicated in acute stroke in NVAF. 
On the other hand, ambulatory cancer patients 
who are stable and receive oral anticancer treat‑
ment along with oral anticoagulants, could con‑
tinue VKA or NOAC after hospital discharge giv‑
en the absence of bleeding prior to ACS. Most pa‑
tients with breast or prostate cancer who receive 
anticancer therapy for a few years do not require 
a few months on heparins after ACS. During tri‑
ple therapy in cancer patients, VKA should be ti‑
trated to obtain international normalized ratio 
(INR) of less than 2.5 or NOAC at reduced doses 
(FIguRE 1C). Appropriate patient selection for typ‑
ically used triple therapy with an oral anticoagu‑
lant post ACS is of vital importance especially in 
cancer patients with good prognosis who should 
receive optimal management similar to that in 
noncancer individuals.
In some cases, triple antithrombotic therapy, 
involving ASA, clopidogrel, and LMWH/VKA, is 
not used because patients with ACS and cancer 
are commonly considered at high risk of bleed‑
ing. The duration of combination therapy with 
LMWH/VKA and clopidogrel varies depending 
on the cancer status of the patient and potential 
bleeding complications during therapy. The maxi‑
mum duration is 12 months of dual antithrombot‑
ic therapy in cancer patients, followed by a mono‑
therapy with oral anticoagulants or LMWH if ac‑
cepted by a patient, mainly in VTE. LMWH is typ‑
ically used for up to 6 weeks, followed by a VKA 
unless contraindicated due to the disease progres‑
sion and poor prognosis. In everyday practice, 
LMWH is used on the long ‑term basis in patients 
with metastatic cancer in the case of high bleed‑
ing risk, frequent liver injury,  and poor progno‑
sis. Monitoring of renal function and blood cell 
count in cancer patients on LMWH is needed.
When deciding on a therapy with VKA, its lim‑
itations in patients with cancer should be consid‑
ered.8 It is much more difficult to achieve the ther‑
apeutic INR in these patients owing to the pres‑
ence of cancer, use of chemotherapy and radio‑
therapy, possible surgical procedures, throm‑
bocytopenia, or concomitant chronic kidney 
disease.22,27 The INR also depends on the diet, 
progression of anorexia, vomiting, a decrease in 
albumin levels, difficult vascular access, and im‑
mobilization. Due to a higher risk of bleeding 
complications, including gastrointestinal bleed‑
ing, gastroprotection with proton pump inhibi‑
tors (PPIs), or H2 ‑receptor antagonists in case of 
intolerance, is recommended during combined 
antiplatelet and anticoagulant therapy.
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a reversal agent for rivaroxaban and apixaban 
administered intravenously, awaits approval by 
the Food and Drug Administration.55 At present, 
life ‑threatening bleeding in patients treated with 
factor Xa inhibitors should be treated with 1500 
to 2000 U of 4 ‑factor prothrombin complex con‑
centrate (like in patients receiving VKA). Recom‑
binant activated factor VII (off ‑label indication) 
might be used if other agents are ineffective.55,56
Bleeding complications in patients with ACS 
and cancer are often an indication for a temporary 
or total withdrawal of antiplatelet and/or antico‑
agulant therapy, which may result in an increased 
risk of thrombotic complications. The risk of stent 
thrombosis increases after 5 days since withdraw‑
al of the antiplatelet drugs in the first 30 days af‑
ter PCI.59 The final decision should be based on 
the severity of bleeding.41,60,61,62 In the case of 
minor bleeding (mucocutaneous or subconjunc‑
tival bleeding, large hematomas), DAPT can be 
continued. If the patient was on oral anticoagu‑
lation, the therapy can be continued or stopped 
for 24 hours. In the case of clinically relevant non‑
major bleeding (nosebleed, hemoptysis, lower or 
upper gastrointestinal bleeding, bleeding from 
the urinary or genital tract that require medical 
contact), which do not require hospitalization, 
DAPT can be continued or its duration can be re‑
duced. Oral anticoagulation should be stopped for 
24 to 48 hours, and when restarted, a VKA with 
an INR of 2 to 2.5 is preferred.
Triple antithrombotic therapy can be replaced 
by dual therapy with clopidogrel plus VKA and 
simultaneous use of a PPI. In patients with se‑
vere bleeding (defined as a decrease in hemo‑
globin levels by more than 2 g/dl and a need for 
hospitalization), the cause of bleeding should 
be established. DAPT can be restarted after 3 to 
7 days, and a shorter duration of this combina‑
tion therapy should be considered. In patients 
on oral anticoagulation, its withdrawal for 5 to 
7 days or the use of an antidote should be con‑
sidered (in patients with mechanical heart valve 
or left ventricular assist device, unfractionated 
heparin [UFH] or LMWH should be used instead, 
for 4 to 8 days). The cause of bleeding should be 
established. Triple therapy should be switched 
to UFH/LMWH treatment (for the duration of 
diagnostic workup or active cancer treatment) 
plus clopidogrel. Then, clopidogrel alone should 
be used. In case of upper gastrointestinal bleed‑
ing, a PPI should be used (intravenous and then 
oral). Severe bleeding in all patients, including 
cancer patients, requires aggressive treatment 
including red blood cell and platelet transfusion, 
endoscopic and surgical procedures. Before re‑
starting antiplatelet drug or drugs (3 to 7 days in 
stable clinical condition), the risk ‑to ‑benefit ra‑
tio of this therapy should be assessed. Most of‑
ten, DAPT should be discontinued and clopido‑
grel alone should be used.
In individuals receiving oral anticoagulation, 
the therapy should be stopped for 7 days and 
the use of an antidote should be considered, 
•	  In case of an urgent surgery for cancer in pa‑
tients with ACS, clopidogrel should be stopped 
5 days before the procedure, while ASA should 
be continued.
•	  After surgery, clopidogrel should be restart‑
ed, first at a loading dose of 300 mg, followed by 
a maintenance dose of 75 mg 24 to 72 hours after 
surgery provided that hemostasis is maintained.
•	  In patients at high thrombotic risk in whom 
clopidogrel is discontinued, bridging therapy with 
GP IIb/IIIa ‑receptor inhibitors (tirofiban or ep‑
tifibatide) administered intravenously should be 
considered. The therapy should be administered 
3 days before the surgery and stopped 4 hours 
before the procedure.
•	  Replacement of antiplatelet drugs with stan‑
dard heparin or LMWH is not recommended in 
cancer patients post ACS.
Bleeding events during antithrombotic therapy in can-
cer patients The occurrence of bleeding or a high‑
er risk of bleeding at baseline in patients with ACS 
increases in ‑hospital mortality.50,51 Importantly, 
the clinical consequences of bleedings vary de‑
pending on the type of bleeding. Clinically rel‑
evant, severe or life ‑threatening bleedings re‑
quire modifications of management. The issue be‑
comes even more complicated in cancer patients 
with ACS because recent major bleeding has so 
far been an exclusion criterion in all randomized 
clinical trials on ACS.51 The question whether to 
continue, withdraw, or temporarily discontinue 
the antiplatelet or anticoagulant therapy (or both) 
in ACS patients who experienced major bleeding 
is challenging and an individualized approach is 
recommended. The risk of thrombosis should be 
balanced against the risk of bleeding, and the cli‑
nician should be prepared to substantially modify 
the decision depending on the clinical scenario.
If severe bleeding occurs in ACS patients on tri‑
ple therapy, the first step is to decide on the use 
of an antidote and blood transfusion.52,53 How‑
ever, red blood cell transfusion increases the risk 
of thrombotic events and enhances inflammatory 
state, which is particularly important in patients 
with ACS and cancer.22,54 Therefore, the decision 
to perform red blood cell transfusion should be 
guided by hemoglobin levels (<7 g/dl), but also 
by the presence of clinical symptoms of anemia. 
If a bleeding complication occurs in a patient on 
antiplatelet therapy, platelet transfusion should 
be considered. If the patient was on a VKA, then 
vitamin K, frozen plasma, prothrombin complex 
concentrate should be used. If the patient was on 
dabigatran, anticoagulant effects of this drug can 
be reversed by a humanized monoclonal antibody 
fragment, idarucizumab, that binds unbound and 
thrombin ‑bound dabigatran.55-58 Idarucizumab 
is administered at 2 doses of 2.5 mg IV given no 
more than 15 minutes apart. In the REVERSE‑
‑AD study, 8.5% of dabigatran ‑treated patients 
who required reversal of its activity suffered from 
cancer, and no signal of lower efficacy or safety 
in this subgroup was noted.58 Andexanet alfa, 
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Thrombocytopenia in cancer patients with acute cor-
onary syndrome About 10% to 25% of cancer pa‑
tients have thrombocytopenia, defined as a plate‑
let count of less than 100 000/µl.22,67-69 Throm‑
bocytopenia induced by chemotherapy or treat‑
ment with heparin, fibrinolytic drugs, clopido‑
grel, or GP IIb/IIIa receptor inhibitors increases 
the risk of major bleeding and other cardiovas‑
cular events.70 There is currently no convincing 
evidence for the minimum platelet count that 
would constitute an absolute contraindication to 
coronary angiography.68 Therefore, it is assumed 
that if a platelet count is between 40 000/µl and 
50 000/µl and there are no other thrombotic dis‑
orders, PCIs are safe.
It seems that in the context of antiplatelet ther‑
apy the platelet function is more important than 
the platelet count. Unfortunately, there are cur‑
rently no tests that would allow a reliable assess‑
ment of platelet function in patients with can‑
cer and thrombocytopenia or that would guide 
the decision making in terms of platelet trans‑
fusion or the duration of DAPT.22 Thromboelas‑
tography might be used to assess blood coagula‑
tion if the platelet count is lower than 30 000/µl; 
however, the method is poorly standardized, not 
widely available, and data interpretation could be 
difficult. If the platelet count is above 10 000/µl, 
ASA therapy can be continued and prophylactic 
platelet transfusion should not be performed; dis‑
continuation of ASA would worsen the progno‑
sis of patients with ACS. If the platelet count is 
lower than 10 000/µl, platelet transfusion is rec‑
ommended.71 Prophylactic platelet transfusion 
should be considered if the platelet count is low‑
er than 20 000/µl and the patient has high fever, 
leukocytosis, a sudden decrease in platelet count 
(heparin ‑induced thrombocytopenia should be ex‑
pected if any heparin is used) or other coagula‑
tion disorders, or if the patient is on chemother‑
apy due to bladder, reproductive, or large intes‑
tine cancer, or melanoma. Combination of ASA 
with clopidogrel is allowed if the platelet count is 
higher than 30 000/µl.72 The starting dose of UFH 
if the platelet count is 50 000/ml or lower should 
be 30 to 50 U/kg.22 If the platelet count exceeds 
50 000/µl, UFH at a dose of 50 to 70 U/kg or bil‑
ivarudin IV should be used. If the activated clot‑
ting time (ACT) is less than 250 seconds during 
the infusion of UFH, the heparin dose should be 
increased. ACT monitoring is crucial for patient 
safety in this clinical setting.
Key messages
•	  Thrombocytopenia induced by chemotherapy 
or treatment with heparin, thrombolytic drugs, 
clopidogrel, or GP IIb/IIIa ‑receptor blockers in‑
creases the risk of bleeding complications and 
other cardiovascular events.
•	  PCIs are safe in patients with a platelet count 
between 40 000 and 50 000/µl and no thrombot‑
ic disorders.
•	  If the platelet count is higher than 10 000/µl, 
ASA can be continued and prophylactic platelet 
transfusion should not be used in patients with 
except in patients with mechanical heart valve 
or left ventricular assist device. UFH or LMWH 
should be introduced again, and VKA therapy 
(INR of 2 to 2.5) should be started after the com‑
pletion of cancer treatment. Triple therapy should 
be switched to LMWH, followed by a VKA in 
combination with clopidogrel. If the bleeding 
occurs during the use of an oral anticoagulant 
and antiplatelet drug, LMWH alone, followed by 
a VKA alone, should be used after the bleeding is 
stopped. In the case of life ‑threatening bleeding, 
fluid infusion, blood product transfusion, endo‑
scopic or surgical procedures, and discontinua‑
tion of DAPT are recommended. Before restart‑
ing the patient on clopidogrel alone (>5 days), 
the thrombotic risk should be balanced against 
the risk of bleeding. If the patient is on oral an‑
ticoagulation, the anticoagulant should be with‑
drawn, and an antidote should be used. Once 
the bleeding is stopped, UFH/LMWH can be used 
after 7 days, but the patient’s clinical condition 
should be carefully monitored. As gastroprotec‑
tive treatment, a PPI may be used (eg, pantopra‑
zole, an IV bolus of 80 mg, followed by an IV infu‑
sion of 8 mg/h for 72 hours and then 20 to 40 mg 
orally twice daily). An alternative treatment (pre‑
ferred in our center) is a bolus infusion of pan‑
toprazole at a dose of 80 mg and then 40 mg IV 
every 12 hours for 72 hours, followed by oral ad‑
ministration of 20 to 40 mg twice daily.63
Key messages
•	  The occurrence of bleeding complications or 
the higher risk of bleeding at baseline in patients 
with ACS increases in ‑hospital mortality.
•	  The clinical consequences of bleedings are var‑
ied and depend on the type of bleeding.
•	  The decision whether to continue, temporarily 
discontinue, or withdraw the antiplatelet and/or 
anticoagulant therapy should be based on the se‑
verity of bleeding, careful risk ‑to ‑benefit assess‑
ment, and the clinical status.
Cardiac surgery in cancer patients with acute coro-
nary surgery Some patients with ACS and can‑
cer require urgent CABG. It is well known that 
CABG in the first 7 days after ACS is associated 
with high risk of mortality and MI. Therefore, 
the optimal time to perform CABG after ACS is 
2 to 6 weeks in clinically stable patients.15,64,65 For 
safety reasons, the platelet count at the time of 
CABG should exceed 50 000/µl.29 A mini ‑invasive 
surgery should be considered to minimize bleed‑
ing in all cancer patients who require cardiac sur‑
gery. In patients who have undergone prior radi‑
ation therapy, computed tomography to evaluate 
the degree of mediastinal fibrosis should be per‑
formed and an angiographic assessment of the in‑
ternal thoracic artery should be made before de‑
ciding on CABG.66
Key messages
•	  CABG should be scheduled 2 to 6 weeks after 
ACS in clinically stable patients with cancer.
•	  CABG should be performed in patients with a 
platelet count exceeding 50 000/µl.
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ACS, while at the platelet count below 10 000/µl, 
platelet transfusion should be performed.
•	  Prophylactic platelet transfusion can be per‑
formed if the platelet count is below 20 000/µl 
and the patient has high fever, leukocytosis, a sud‑
den decrease in the platelet count or other coag‑
ulation disorders, or if the patient is on chemo‑
therapy due to bladder, ovarian, colon cancer, or 
melanoma.
•	  Combination of ASA with clopidogrel is al‑
lowed if the platelet count exceeds 30 000/µl giv‑
en the absence of active bleeding.
Conclusions The current limited evidence indi‑
cates that each patient with cancer, at any stage 
of its diagnosis and treatment, who develops ACS 
should be managed according to the guidelines 
recommended for noncancer patients, includ‑
ing invasive strategy whenever possible. In each 
case, the risk ‑to ‑benefit ratio of the recommend‑
ed treatment should be carefully assessed before 
making the therapeutic decision and regularly re‑
assessed. Chemotherapy and surgery as potent 
prothrombotic factors that disturb therapy post 
ACS require specialist consults, particularly with‑
in the first weeks following acute myocardial isch‑
emia. Given increased bleeding risk in cancer pa‑
tients, antithrombotic treatment following ACS 
should be carefully monitored and not prolonged 
above the recommended duration.
Since prognosis has considerably improved in 
many cancer patients in the last decade, optimal 
therapy of ACS may increase the life expectancy 
and reduce the risk of adverse coronary events 
after ACS in this high ‑risk population.
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